Literature DB >> 32279093

Imidazole derivatives as antiparasitic agents and use of molecular modeling to investigate the structure-activity relationship.

Oluyomi Stephen Adeyemi1,2, Abiodun Omokehinde Eseola3,4, Winfried Plass3, Olubunmi Atolani5, Tatsuki Sugi6, Yongmei Han6,7, Gaber El-Saber Batiha6,8, Kentaro Kato6,9, Oluwakemi Josephine Awakan10, Tomilola Debby Olaolu10, Charles Obiora Nwonuma10, Omokolade Alejolowo10, Akinyomade Owolabi11, Damilare Rotimi10, Omowumi Titilola Kayode10.   

Abstract

Toxoplasmosis is a common parasitic disease caused by Toxoplasma gondii. Limitations of available treatments motivate the search for better therapies for toxoplasmosis. In this study, we synthesized a series of new imidazole derivatives: bis-imidazoles (compounds 1-8), phenyl-substituted 1H-imidazoles (compounds 9-19), and thiopene-imidazoles (compounds 20-26). All these compounds were assessed for in vitro potential to restrict the growth of T. gondii. To explore the structure-activity relationships, molecular analyses and bioactivity prediction studies were performed using a standard molecular model. The in vitro results, in combination with the predictive model, revealed that the imidazole derivatives have excellent selectivity activity against T. gondii versus the host cells. Of the 26 compounds screened, five imidazole derivatives (compounds 10, 11, 18, 20, and 21) shared a specific structural moiety and exhibited significantly high selectivity (> 1176 to > 27,666) towards the parasite versus the host cells. These imidazole derivatives are potential candidates for further studies. We show evidence that supports the antiparasitic action of the imidazole derivatives. The findings are promising in that they reinforce the prospects of imidazole derivatives as alternative and effective antiparasitic therapy as well as providing evidence for a probable biological mechanism.

Entities:  

Keywords:  Drug discovery; Infectious diseases; Medicinal biochemistry; Medicinal chemistry

Mesh:

Substances:

Year:  2020        PMID: 32279093     DOI: 10.1007/s00436-020-06668-6

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  3 in total

1.  Triazole-based compound as a candidate to develop novel medicines to treat toxoplasmosis.

Authors:  Katarzyna Dzitko; Agata Paneth; Tomasz Plech; Jakub Pawełczyk; Lidia Węglińska; Piotr Paneth
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

2.  Modulation of host HIF-1α activity and the tryptophan pathway contributes to the anti-Toxoplasma gondii potential of nanoparticles.

Authors:  Oluyomi Stephen Adeyemi; Yuho Murata; Tatsuki Sugi; Yongmei Han; Kentaro Kato
Journal:  Biochem Biophys Rep       Date:  2017-07-05

3.  A Perspective on Thiazolidinone Scaffold Development as a New Therapeutic Strategy for Toxoplasmosis.

Authors:  Cristian Rocha-Roa; Diego Molina; Néstor Cardona
Journal:  Front Cell Infect Microbiol       Date:  2018-10-16       Impact factor: 5.293

  3 in total
  5 in total

1.  Exploring the Antiparasitic Activity of Tris-1,3,4-Thiadiazoles against Toxoplasma gondii-Infected Mice.

Authors:  Tahani M Almutairi; Nadjet Rezki; Mohamed Reda Aouad; Mohamed Hagar; Basant A Bakr; Moaaz T Hamed; Maha Khairy Hassen; Bassma H Elwakil; Esraa Abdelhamid Moneer
Journal:  Molecules       Date:  2022-03-30       Impact factor: 4.411

2.  Pyromellitic diamide-diacid bridged mesoporous organosilica nanospheres with controllable morphologies: a novel PMO for the facile and expeditious synthesis of imidazole derivatives.

Authors:  Ehsan Valiey; Mohammad G Dekamin
Journal:  Nanoscale Adv       Date:  2021-11-04

3.  Computational study of the therapeutic potentials of a new series of imidazole derivatives against SARS-CoV-2.

Authors:  Titilayo O Johnson; Abayomi Emmanuel Adegboyega; Opeyemi Iwaloye; Omokehinde Abiodun Eseola; Winfried Plass; Boluwatife Afolabi; Damilare Rotimi; Eman I Ahmed; Ashraf Albrakati; Gaber E Batiha; Oluyomi Stephen Adeyemi
Journal:  J Pharmacol Sci       Date:  2021-05-23       Impact factor: 3.337

4.  New Series of Imidazoles Showed Promising Growth Inhibitory and Curative Potential Against Trypanosoma Infection.

Authors:  Oluyomi Stephen Adeyemi; Nthatisi Innocentia Molefe-Nyembe; Abiodun Omokehinde Eseola; Winfried Plass; Oluwatosin Kudirat Shittu; Ibrahim Olatunji Yunusa; Olubunmi Atolani; Ikponmwosa Owen Evbuomwan; Oluwakemi J Awakan; Keisuke Suganuma; Kentaro Kato
Journal:  Yale J Biol Med       Date:  2021-06-30

5.  Imidazole as a Promising Medicinal Scaffold: Current Status and Future Direction.

Authors:  Sahar S Alghamdi; Rasha S Suliman; Khlood Almutairi; Khawla Kahtani; Dimah Aljatli
Journal:  Drug Des Devel Ther       Date:  2021-07-29       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.